Prevail Partners
Prevail Partners is a venture capital firm based in Philadelphia, founded in 2008, that specializes in investing in life sciences companies. The firm targets sectors such as therapeutics, preventive treatments, medical devices, and diagnostics, aiming to leverage promising scientific advancements for attractive returns. A distinctive aspect of Prevail Partners is its application of proprietary technologies and services through Prevail InfoWorks, which enhances the likelihood of success in clinical trials for its portfolio companies. This strategic approach provides confidence to investors and potential licensing partners regarding the viability of their investments.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.
PolyPhotonix is pioneering the early adoption of organic light. Working with designers and key customers, it is creating new products and supporting the design process right through to manufacture based at the National Printable Electronics Centre.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.